Swedish Ibrance Registries Insights (SIRI)
Launched by PFIZER · Nov 27, 2020
Trial Information
Current as of May 06, 2025
Recruiting
Keywords
ClinConnect Summary
The Swedish Ibrance Registries Insights (SIRI) trial is studying how patients with breast cancer are treated with a medication called palbociclib in Sweden. The main goal of this study is to understand the characteristics of patients, the treatment methods they use, and the results of their treatment. This information can help improve care for people with breast cancer in the future.
To participate in this study, you need to be at least 18 years old and have received at least one prescription for palbociclib. There are no specific exclusions, so many patients may be eligible. If you join the trial, you can expect to share information about your treatment and health, which will contribute to a better understanding of how palbociclib works for breast cancer patients. The study is currently looking for participants, so it’s a great opportunity to be part of important research that could benefit others.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- • 1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
- • 2. Age ≥18 years at index date
- Exclusion Criteria:
- • There are no exclusion criteria
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sollentuna, , Sweden
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials